Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min(-1). The starting dose was 6 mg DXR equivalent m(-2), and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m(-2). Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m(-2) (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C(5 min) and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m(-2) every 3 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This same concept was used by Kataoka and colleagues in a series of works leading to development of polymeric micelle NK911, which was evaluated clinically [146, 147].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationWHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639 · cited 2×
“Dose escalation was performed according to the previously described accelerated titration method (Simon et al, 1997).”
MethodDevelopment of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570 · cited 7×
“The hydrophobic inner core enables NK911 to entrap a sufficient amount of DXR. NK911 has a diameter of about 40 nm (Nakanishi et al, 2001).”
BackgroundMethodSelf-citationUziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477 · cited 1×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
Background(1991) · PubMed · Cited by 418
Cited by
Items 101–200 of 621
Targeted nanoparticles for detecting and treating cancer
Sunderland, C. J., Steiert, M., Talmadge, J. E., Derfus, A. M., & Barry, S. E. (2006) · Drug Development Research · doi:10.1002/ddr.20069 · Cited by 200
“…copolymer formulations of diammino and diaminocyclohexane platinum bioactive agents with extended distribution in mice and better efficacy in certain mouse tumor studies [Cabral et al., 2005] while doxorubicin-loaded BCMs have advanced into human clinical trials in Japan [Matsumura et al., 2004].”
BackgroundBlock copolymer micelles as delivery vehicles of hydrophobic drugs: Micelle–cell interactions
Savić, R., Eisenberg, A., & Maysinger, D. (2006) · Journal of Drug Targeting · doi:10.1080/10611860600874538 · Cited by 218
“For example, in a doxorubicin trial (Matsumura et al. 2004), the drug was incorporated in doxorubicin–poly(aspartic acid)–b– poly(ethylene glycol) micelles and administered onceevery-three weeks to patients with metastatic or recurrent solid tumors.”
BackgroundResultInfluentialZhao, L., Du, J., Duan, Y., Zang, Y., Zhang, H., Yang, C., Cao, F., & Zhai, G. (2012) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2012.04.017 · Cited by 216
Lv, S., Li, M., Tang, Z., Song, W., Sun, H., Liu, H., & Chen, X. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.08.015 · Cited by 213
“Accordingly, several polymeric nanoparticles of PEG-PAA incorporating doxorubicin, paclitaxel, SN-38 and cisplatin exhibited significant antitumor efficacy with appreciably lowered toxicity compared with free drugs, and are currently under clinical evaluation [23–26].”
BackgroundMima, Y., Hashimoto, Y., Shimizu, T., Kiwada, H., & Ishida, T. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00144 · Cited by 209
Temperature-responsive polymeric micelles for optimizing drug targeting to solid tumors
Akimoto, J., Nakayama, M., & Okano, T. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.062 · Cited by 204
Polymeric micelles as drug carriers: their lights and shadows
Yokoyama, M. (2014) · Journal of Drug Targeting · doi:10.3109/1061186x.2014.934688 · Cited by 205
“For poly(ethylene glycol)-b-poly(amino acid) block copolymer-based polymeric micelle anti-cancer drugs, carrier-derived toxic side effects were not observed both in animal experiments or in clinical evaluations, while typical toxicities of anti-cancer drugs loaded in the polymeric micelles were observed to appear [47,…”
BackgroundPolymer genomics: An insight into pharmacology and toxicology of nanomedicines☆
KABANOV, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.019 · Cited by 204
Polymeric micelles for drug targeting
Mahmud, A., Xiong, X.-B., Aliabadi, H. M., & Lavasanifar, A. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701538586 · Cited by 202
Hu, C.-M. J., Fang, R. H., Luk, B. T., & Zhang, L. (2014) · Nanoscale · doi:10.1039/c3nr05444f · Cited by 201
Recent advances in nanotheranostics for triple negative breast cancer treatment
Thakur, V., & Kutty, R. V. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1443-1 · Cited by 200
Ferrari, R., Sponchioni, M., Morbidelli, M., & Moscatelli, D. (2018) · Nanoscale · doi:10.1039/c8nr05933k · Cited by 189
Doxorubicin‐Conjugated Immuno‐Nanoparticles for Intracellular Anticancer Drug Delivery
Shi, M., Ho, K., Keating, A., & Shoichet, M. S. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200801271 · Cited by 186
Meng, F., Zhong, Y., Cheng, R., Deng, C., & Zhong, Z. (2014) · Nanomedicine · doi:10.2217/nnm.13.212 · Cited by 188
Zhang, W., Shi, Y., Chen, Y., Yu, S., Hao, J., Luo, J., Sha, X., & Fang, X. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.04.017 · Cited by 180
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Clinical translation of nanomedicines
Svenson, S. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.001 · Cited by 175
Wu, Y., Chen, W., Meng, F., Wang, Z., Cheng, R., Deng, C., Liu, H., & Zhong, Z. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.011 · Cited by 172
Piktel, E., Niemirowicz, K., Wątek, M., Wollny, T., Deptuła, P., & Bucki, R. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0193-x · Cited by 171
“National Institutes of Health [41].”
Clinical Developments in Nanotechnology for Cancer Therapy
Heidel, J. D., & Davis, M. E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0178-7 · Cited by 170
“half-life (t1/2), while free doxorubicin alone has a t1/2 of less than an hour (36), the micellar formulations extended the plasma half-life by approximately three-fold (37,38), while the liposomal formulations extended it further by more than an additional ten-fold (36,39,40) (see Table I).”
Nakayama, M., & Okano, T. (2005) · Biomacromolecules · doi:10.1021/bm050232w · Cited by 169
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
“The amphiphilic property of micelles makes them suitable for delivering either hydrophilic or hydrophobic therapeutics, generating various micellebased formulations under clinical investigation (78, 139, 158, 265, 340, 476).”
BackgroundAntibody-modified liposomes for cancer chemotherapy
Torchilin, V. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.9.1003 · Cited by 168
“The same set of indications was targeted by the combination therapy involving liposomal doxorubicin and paclitaxel [62] or Doxil/Caelyx (doxorubicin in PEG-liposomes) and carboplatin [63] .”
MethodInfluentialClinical application of polymeric micelles for the treatment of cancer
Varela-Moreira, A., Shi, Y., Fens, M. H. A. M., Lammers, T., Hennink, W. E., & Schiffelers, R. M. (2017) · Materials Chemistry Frontiers · doi:10.1039/c6qm00289g · Cited by 168
Eetezadi, S., Ekdawi, S. N., & Allen, C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.001 · Cited by 166
Targeted Nanoparticles for Colorectal Cancer
Cisterna, B. A., Kamaly, N., Choi, W. I., Tavakkoli, A., Farokhzad, O. C., & Vilos, C. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0194 · Cited by 166
Cai, S., Thati, S., Bagby, T. R., Diab, H.-M., Davies, N. M., Cohen, M. S., & Forrest, M. L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.006 · Cited by 163
“Technologies such as polymeric micelles [2], synthetic polymer conjugates [3], and antibody targeted carriers [4] have demonstrated reduced or altered toxicity in Phase I trials, yet the therapeutic efficacy of these formulations has yet to demonstrated.”
BackgroundAmphiphilic poly(l-amino acids) — New materials for drug delivery
Lalatsa, A., Schätzlein, A. G., Mazza, M., Le, T. B. H., & Uchegbu, I. F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.046 · Cited by 163
Kong, X., Qi, Y., Wang, X., Jiang, R., Wang, J., Fang, Y., Gao, J., & Chu Hwang, K. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101070 · Cited by 161
Fate of micelles and quantum dots in cells
Maysinger, D., Lovrić, J., Eisenberg, A., & Savić, R. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.08.011 · Cited by 160
Combined cancer therapy by micellar-encapsulated drug and ultrasound
Rapoport, N. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.048 · Cited by 159
The in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154
Yang, R., Meng, F., Ma, S., Huang, F., Liu, H., & Zhong, Z. (2011) · Biomacromolecules · doi:10.1021/bm2006856 · Cited by 149
Amphiphilic block copolymer micelles for nanoscale drug delivery
Kwon, G. S., & Forrest, M. L. (2006) · Drug Development Research · doi:10.1002/ddr.20063 · Cited by 148
“Thus, PEO-b-PAsp-DOX micelles are being evaluated in Phase II clinical trials at the National Cancer Institute in Japan with an emphasis on pancreatic cancer [Matsumura et al., 2004].”
BackgroundNanomedicines for the treatment of hematological malignancies
Deshantri, A. K., Varela-Moreira, A., Ecker, V., Mandhane, S. N., Schiffelers, R. M., Buchner, M., & Fens, M. H. A. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.034 · Cited by 161
Ke, X., Ng, V. W. L., Ono, R. J., Chan, J. M. W., Krishnamurthy, S., Wang, Y., Hedrick, J. L., & Yang, Y. Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.061 · Cited by 146
Yang, Y., Pan, D., Luo, K., Li, L., & Gu, Z. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.037 · Cited by 154
Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases
Dheer, D., Nicolas, J., & Shankar, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.010 · Cited by 144
Hamaguchi, T., Doi, T., Eguchi-Nakajima, T., Kato, K., Yamada, Y., Shimada, Y., Fuse, N., Ohtsu, A., Matsumoto, S.-I., Takanashi, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0387 · Cited by 144
Self-citationNanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management
Tagde, P., Najda, A., Nagpal, K., Kulkarni, G. T., Shah, M., Ullah, O., Balant, S., & Rahman, M. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052856 · Cited by 159
Formulation of Drugs in Block Copolymer Micelles: Drug Loading and Release
Liu, J., Lee, H., & Allen, C. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206779026263 · Cited by 143
Yang, C. H., Attia, A. B. E., Tan, J. P. K., Ke, X., Gao, S., Hedrick, J. L., & Yang, Y. Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.035 · Cited by 155
Building nanostructures with drugs
Ma, W., Cheetham, A. G., & Cui, H. (2016) · Nano Today · doi:10.1016/j.nantod.2015.11.003 · Cited by 146
Stimulus-responsive self-assembled prodrugs in cancer therapy
Dong, X., Brahma, R. K., Fang, C., & Yao, S. Q. (2022) · Chemical Science · doi:10.1039/d2sc01003h · Cited by 143
Ryan, G. M., Kaminskas, L. M., & Porter, C. J. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.051 · Cited by 141
Multi-stage delivery nano-particle systems for therapeutic applications
Serda, R. E., Godin, B., Blanco, E., Chiappini, C., & Ferrari, M. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.05.004 · Cited by 157
“This formulation, known as NK911, displayed long blood circulation times and nearly tripled the half-life of doxorubicin [81].”
BackgroundBanu, H., Sethi, D. K., Edgar, A., Sheriff, A., Rayees, N., Renuka, N., Faheem, S. M., Premkumar, K., & Vasanthakumar, G. (2015) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2015.05.008 · Cited by 139
Perche, F., Patel, N. R., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.003 · Cited by 135
“Formulation of doxorubicin as micelles or liposomes has shown good clinical activity with reduced adverse toxicity [15, 16].”
BackgroundDrug and Gene Delivery Based on Supramolecular Assembly of PEG-Polypeptide Hybrid Block Copolymers
Osada, K., & Kataoka, K. (2006) · Springer eBooks · doi:10.1007/12_084 · Cited by 146
Nanotechnology approaches in the current therapy of skin cancer
Borgheti-Cardoso, L. N., Viegas, J. S. R., Silvestrini, A. V. P., Caron, A. L., Praça, F. S. G., Kravicz, M., & Bentley, M. V. L. B. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.005 · Cited by 148
Progress in Polymeric Nano-Medicines for Theranostic Cancer Treatment
Ali, I., Alsehli, M., Scotti, L., Tullius Scotti, M., Tsai, S.-T., Yu, R.-S., Hsieh, M. F., & Chen, J.-C. (2020) · Polymers · doi:10.3390/polym12030598 · Cited by 134
Carrier-free nanomedicines for cancer treatment
Liu, L., & Zhang, X. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2021.100919 · Cited by 142
Ring-Opening Polymerization-Mediated Controlled Formulation of Polylactide−Drug Nanoparticles
Tong, R., & Cheng, J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja8084675 · Cited by 150
Colloidal particles for cellular uptake and delivery
Hu, L., Mao, Z., & Gao, C. (2009) · Journal of Materials Chemistry · doi:10.1039/b815958k · Cited by 156
Redox-Sensitive Hydroxyethyl Starch–Doxorubicin Conjugate for Tumor Targeted Drug Delivery
Hu, H., Li, Y., Zhou, Q., Ao, Y., Yu, C., Wan, Y., Xu, H., Li, Z., & Yang, X. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b11932 · Cited by 131
Hande, K. R. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.04.001 · Cited by 131
Yokoyama, M. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.06.002 · Cited by 152
Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting
Lee, J., Choi, M., & Song, I. (2023) · Pharmaceuticals · doi:10.3390/ph16060802 · Cited by 160
“Both intravenous and orally administered NaHCO3 showed clear DOX accumulation in the tumor tissue as well as a 9- and 2-fold decrease in tumor size compared with free DOX and Doxil alone, respectively.”
BackgroundInfluentialA concise review on cancer treatment methods and delivery systems
Bidram, E., Esmaeili, Y., Ranji‐Burachaloo, H., Al-Zaubai, N., Zarrabi, A., Stewart, A. G., & Dunstan, D. E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101350 · Cited by 141
Rational design of polymeric micelles for targeted therapeutic delivery
Zheng, Y., Oz, Y., Gu, Y., Ahamad, N., Shariati, K., Chevalier, J. M., Kapur, D., & Annabi, N. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102147 · Cited by 124
“While the prolonged stability of polymeric micellar drug carriers in the circulation enhances the biodistribution of the encapsulated APIs, it can also lead to potential damage to off-target tissues [11 – 13].”
Smart polymeric micelles for gene and drug delivery
Nishiyama, N., Bae, Y., Miyata, K., Fukushima, S., & Kataoka, K. (2005) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2005.05.007 · Cited by 132
Talelli, M., Rijcken, C. J. F., Oliveira, S., van der Meel, R., Henegouwen, P. M. P. V. B. E., Lammers, T., van Nostrum, C. F., Storm, G., & Hennink, W. E. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.015 · Cited by 120
Sohail, M., Sun, Z., Li, Y., Gu, X., & Xu, H. Z. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1991316 · Cited by 120
Amphiphilic block co-polymers: Preparation and application in nanodrug and gene delivery
Xiong, X.-B., Binkhathlan, Z., Molavi, O., & Lavasanifar, A. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.03.006 · Cited by 125
Mokhtarzadeh, A., Alibakhshi, A., Hejazi, M., Omidi, Y., & Dolatabadi, J. E. N. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2016.06.013 · Cited by 123
Zeng, F., Lee, H., & Allen, C. (2006) · Bioconjugate Chemistry · doi:10.1021/bc050350g · Cited by 110
Multifunctional nanoparticles for use in theranostic applications
Cole, J. T., & Holland, N. B. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0218-2 · Cited by 123
An overview of polymeric nanomicelles in clinical trials and on the market
Zheng, X., Xie, J., Zhang, X., Sun, W., Zhao, H., Li, Y., & Wang, C. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.11.029 · Cited by 114
Challenges facing colloidal delivery systems: From synthesis to the clinic
Johnston, A. P. R., Such, G. K., Ng, S. L., & Caruso, F. (2010) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2010.11.003 · Cited by 124
Raza, K., Kumar, D., Thakur, C. K., Kumar, M., Guru, S. K., Kumar, P., Arora, S., Sharma, G., Bhushan, S., & Katare, O. P. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00183 · Cited by 107
Application of advances in endocytosis and membrane trafficking to drug delivery
Ju, Y., Guo, H., Edman, M. C., & Hamm‐Alvarez, S. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.026 · Cited by 116
Gou, P., Liu, W., Mao, W., Tang, J., Shen, Y., & Sui, M. (2012) · Journal of Materials Chemistry B · doi:10.1039/c2tb00004k · Cited by 105
Lu, H., Utama, R. H., Kitiyotsawat, U., Babiuch, K., Jiang, Y., & Stenzel, M. H. (2014) · Biomaterials Science · doi:10.1039/c4bm00323c · Cited by 114
Xu, Y., Meng, F., Cheng, R., & Zhong, Z. (2009) · Macromolecular Bioscience · doi:10.1002/mabi.200900233 · Cited by 102
Nanoparticles for Targeted and Temporally Controlled Drug Delivery
Swami, A., Shi, J., Gadde, S., Votruba, A. R., Kolishetti, N., & Farokhzad, O. C. (2012) · Nanostructure science and technology · doi:10.1007/978-1-4614-2305-8_2 · Cited by 133
Polymeric Nanoparticles for the Treatment of Malignant Gliomas
Mahmoud, B. S., Alamri, A. H., & McConville, C. (2020) · Cancers · doi:10.3390/cancers12010175 · Cited by 110
Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy
Sun, L., Wu, Q., Peng, F., Liu, L., & Gong, C. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.07.013 · Cited by 105
siRNA Conjugated Nanoparticles—A Next Generation Strategy to Treat Lung Cancer
Itani, R., & Faraj, A. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236088 · Cited by 105
“They have proved their effectiveness against various tumors and reduced side effects making them promising for clinical use [21].”
BackgroundGupta, R., Shea, J., Scaife, C. L., Шурлыгина, А. В., & Rapoport, N. Y. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.019 · Cited by 107
Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems
van Elk, M., Murphy, B. P., Eufrásio-da-Silva, T., O’Reilly, D. P., Vermonden, T., Hennink, W. E., Duffy, G. P., & Ruiz‐Hernández, E. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.013 · Cited by 104
“Several clinical trials have been conducted involving micelles loaded with chemotherapeutic drugs such as cisplatin (Plummer et al., 2011), PTX (Kato et al., 2012; Lee et al., 2013) and DOX (Matsumura et al., 2004; Cabral and Kataoka, 2014) (Table 3).”
Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine
Wang, Q., Atluri, K., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceuticals · doi:10.3390/ph16030433 · Cited by 113
“The most common side effect was neutropenia, but the treatment was generally well tolerated and had a good safety profile [223].”
BackgroundLee, H., Zeng, F., Dunne, M., & Allen, C. (2005) · Biomacromolecules · doi:10.1021/bm050451h · Cited by 95
Recent advances in intravenous delivery of poorly water-soluble compounds
Shi, Y., Porter, W., Merdan, T., & Li, L. C. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903307423 · Cited by 102
“Two micellar formulations of doxorubicin formulatedwith PEG-b-poly(aspartic acid) copolymers are now being studied in various phases of clinical trials [46,47].”
BackgroundMethodBiomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment
Marshall, S. K., Angsantikul, P., Pang, Z., Nasongkla, N., Hussen, R. S. D., & Thamphiwatana, S. (2022) · Molecules · doi:10.3390/molecules27196473 · Cited by 94
“64 million cancer deaths in China and the United States of America [1], respectively.”
BackgroundInfluentialMicellar carriers for the delivery of multiple therapeutic agents
Thipparaboina, R., Chavan, R. B., Kumar, D. K., Modugula, S., & Shastri, N. R. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.07.046 · Cited by 97
Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant
Sharma, A. K., Zhang, L., Li, S., Kelly, D. L., Alakhov, V. Y., Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.031 · Cited by 92
Polymeric micelle nanocarriers in cancer research
Shin, D. H., Tam, Y. T., & Kwon, G. S. (2016) · Frontiers of Chemical Science and Engineering · doi:10.1007/s11705-016-1582-2 · Cited by 99
Overcoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic
Houdaihed, L., Evans, J. C., & Allen, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00188 · Cited by 91
Islam, R., Maeda, H., & Fang, J. Q. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1874916 · Cited by 100
“For example, stability of nanomedicines during their time in circulation is a critical feature that is necessary so that intact, not degraded nanomedicines can extravasate and enter tumor tissues [6,10,19,20].”
BackgroundPolylactide‐cyclosporin A nanoparticles for targeted immunosuppression
Azzi, J. R., Tang, L., Moore, R. F., Tong, R., Haddad, N. E., Akiyoshi, T., Mfarrej, B. G., Yang, S., Jurewicz, M. M., Ichimura, T., et al. (2010) · The FASEB Journal · doi:10.1096/fj.10-154690 · Cited by 89
“The rapid dose dumping causes severe systemic toxicities (30).”
Polymeric micelles with stimuli-triggering systems for advanced cancer drug targeting
Nakayama, M., Akimoto, J., & Okano, T. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.936872 · Cited by 98
“doxorubicin (DOX) [63], paclitaxel (PTX) [64] and cisplatin [65]] have been conducted at both domestic (National Cancer Center in Japan) and foreign sites.”
BackgroundPolypeptide-based drug delivery systems for programmed release
Wang, X., Song, Z., Wei, S., Ji, G., Zheng, X., Fu, Z., & Cheng, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120913 · Cited by 92
Bioreducible polymersomes for intracellular dual-drug delivery
Thambi, T., Deepagan, V. G., Ko, H., Lee, D. S., & Park, J. H. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm34546c · Cited by 89
Folate-conjugated crosslinked biodegradable micelles for receptor-mediated delivery of paclitaxel
Xiong, J., Meng, F., Wang, C., Cheng, R., Liu, Z., & Zhong, Z. (2011) · Journal of Materials Chemistry · doi:10.1039/c0jm04410e · Cited by 88
Past and future evolution in colloidal drug delivery systems
Boyd, B. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.69 · Cited by 88
Osorno, L. L., Brandley, A., Maldonado, D., Yiantsos, A., Mosley, R. J., & Byrne, M. E. (2021) · Nanomaterials · doi:10.3390/nano11020278 · Cited by 94
Current role of nanoparticles in the treatment of lung cancer
Carrasco-Esteban, E., Domínguez-Rullán, J. A., Barrionuevo-Castillo, P., Pelari-Mici, L., Leaman, O., Sastre-Gallego, S., & López‐Campos, F. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202102.005 · Cited by 124
“Attempts have also been made to improve efficacy and reduce side effects by using drugs such as doxorubicin or SN-38 encapsulated within micelles [118,119].”
BackgroundDaga, M., Ullio, C., Argenziano, M., Dianzani, C., Cavalli, R., Trotta, F., Ferretti, C., Zara, G. P., Gigliotti, C. L., Ciamporcero, E. S., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.05.009 · Cited by 96
“Various polymeric vehicles, developed in the past years as carriers for antitumor drugs, such as Dox or paclitaxel, demonstrated inadequate stability [30, 31] or inadequate toxicity against tumor cells compared with the drug alone [32].”
Wang, Y., Hosta‐Rigau, L., Lomas, H., & Caruso, F. (2011) · Physical Chemistry Chemical Physics · doi:10.1039/c0cp02287j · Cited by 94
β-Cyclodextrin-Centered Star-Shaped Amphiphilic Polymers for Doxorubicin Delivery
Li, Q., Wang, R. J., Zheng, C., Jin, Y., & Jin, L. (2010) · Nanomedicine · doi:10.2217/nnm.09.108 · Cited by 90
Metadata
- Authors
- Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N.
- Affiliations
- National Cancer Center Hospital East (JP)
- National Cancer Center Hospital (JP)
- Nippon Kayaku (Japan) (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2004-10-12
- Volume
- 91
- Issue
- 10
- Pages
- 1775-1781
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2410050
- OpenAlex
- W2056347214
- Cited by
- 623
- References
- 17
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 28 · 2021: 35 · 2020: 28 · 2019: 23 · 2018: 25 · 2017: 37 · 2016: 42 · 2015: 38 · 2014: 53 · 2013: 28 · 2012: 54
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- doxorubicin, polymeric micelles, supramolecular nanocarriers, maximum tolerated dose, dose-limiting toxicity, neutropenia, pharmacokinetics, solid tumors, metastatic pancreatic cancer, accelerated titration, recommended phase 2 dose, drug delivery
- MeSH terms
- Aged, Antineoplastic Agents, Doxorubicin, Drug Administration Schedule, Female, Humans, Male, Micelles, Middle Aged, Nausea, Neoplasms, Neutropenia, Peptides, Polyethylene Glycols, Vomiting, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.